You just read:

Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor

News provided by

Inovio Pharmaceuticals, Inc.

Apr 01, 2019, 07:45 ET